Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018;4:18001.

Article  PubMed  Google Scholar 

Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571–84.

Article  PubMed  Google Scholar 

Cushing K, Higgins PDR. Management of Crohn disease: a review. JAMA. 2021;325:69–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–60.

Article  CAS  PubMed  Google Scholar 

Ma X, Xu S. TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep. 2013;1:177–84.

Article  CAS  PubMed  Google Scholar 

Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–106.

Article  PubMed  Google Scholar 

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–72.

Article  PubMed  Google Scholar 

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.

Article  CAS  PubMed  Google Scholar 

Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77:845-854.e5.

Article  PubMed  Google Scholar 

Waljee AK, Higgins PDR, Jensen CB, et al. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol. 2020;5:276–84.

Article  PubMed  Google Scholar 

Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177:1605–12.

Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406–13.

Article  PubMed  Google Scholar 

Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

Article  PubMed  Google Scholar 

Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75.

Article  PubMed  PubMed Central  Google Scholar 

Yoshida S, Tanaka S, Okada M, et al. Develeopment and validation of ischemic heart disease and stroke prognostic models using large-scale real-world data from Japan. Environ Health Prev Med. 2023;28:16.

Article  PubMed  PubMed Central  Google Scholar 

Inose R, Nakamura A, Omi R, et al. Risks of malignant lymphoma in rheumatoid arthritis patients receiving methotrexate-alone and in combination therapy compared with the general population: a study based on a Japanese medical claims database. Int J Clin Pharmacol Ther. 2023;61:430–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raaschou P, Simard JF, Asker Hagelberg C, et al; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ 2016:352:i262.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.

Article  Google Scholar 

Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133(6):601–9.

Article  PubMed  PubMed Central  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26.

Article  CAS  PubMed  Google Scholar 

Cancer Statistics in Japan 2022. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2022_fig_E.pdf. Accessed 23 May 2024

Yu J, Refsum E, Wieszczy P, et al. Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study. BMJ Open Gastroenterol. 2023;10: e001037.

Article  PubMed  PubMed Central  Google Scholar 

Olén O, Smedby KE, Erichsen R, et al. Increasing risk of lymphoma over time in Crohn’s disease but not in ulcerative colitis: a scandinavian cohort study. Clin Gastroenterol Hepatol. 2023;21:3132–42.

Article  PubMed  Google Scholar 

Massano A, Bertin L, Zingone F, et al. Extraintestinal cancers in inflammatory bowel disease: a literature review. Cancers (Basel). 2023;15:3824.

Article  CAS  PubMed  Google Scholar 

Vaengebjerg S, Skov L, Egeberg A, et al. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:421–9.

Article  PubMed  PubMed Central  Google Scholar 

Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased? Arthritis Rheumatol. 2017;69:700–8.

Article  CAS  PubMed  Google Scholar 

Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52:1289–97.

Article  CAS  PubMed  Google Scholar 

Kamstrup MR, Skov L, Zachariae C, et al. Psoriasis and risk of malignant lymphoma: a population-based cohort study. Br J Dermatol. 2018;178:1435–6.

Article  CAS  PubMed  Google Scholar 

Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheumatol. 2004;50:1740–51.

Article  CAS  Google Scholar 

Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheumatol. 2006;54:692–701.

Article  Google Scholar